Biotechnology - Biotechnology, USA

Filter

Current filters:

BiotechnologyUSA

Popular Filters

1 to 25 of 260 results

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

17-12-2014

Biopharma company Emergent BioSolutions has acquired the EV-035 series of molecules from Evolva Holding.

Antibiotics and Infectious diseasesBiotechnologyEmergent BioSolutionsEvolvaLicensingResearchUSA

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

15-12-2014

Oncology specialist Sorrento Therapeutics has entered into a binding agreement with medical technology…

BiotechnologyLicensingOncologyResearchSorrento TherapeuticsUSA

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

15-12-2014

Genentech, the US biotech subsidiary of Swiss Pharma major Roche Group, has submitted a New Drug Application…

BiotechnologycobimetinibExelixisGenentechOncologyRegulationRocheUSAZelboraf

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

15-12-2014

US biotech major Gilead Sciences has appointed Philippe Bishop as senior vice president of hematology…

BiotechnologyBoardroomGilead SciencesHematologyOncologyUSA

Ardelyx appoints Jeremy Caldwell as executive vice president and chief scientific officer

Ardelyx appoints Jeremy Caldwell as executive vice president and chief scientific officer

11-12-2014

Biopharma commpany Ardelyx has appointed Jeremy Caldwell as executive vice president and chief scientific…

ArdelyxBiotechnologyBoardroomJeremy CaldwellUSA

Navidea forms Macrophage Therapeutics unit to explore applications of Manocept

11-12-2014

US biotech firm Navidea Biopharmaceuticals has established a new business unit, Macrophage Therapeutics,…

BiotechnologyLymphoseekMacrophage TherapeuticsManagementManoceptNavidea BiopharmaceuticalsUSA

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

10-12-2014

US law firm Chimicles & Tikellis of Haverford, PA, has filed a law suit on behalf of the Southeastern…

Anti-viralsBiotechnologyGilead SciencesLawLegalPricingSocial IssuesSovaldiUnited StatesUSA

US declaration under PREP Act to support Ebola vaccines development

10-12-2014

US Health and Human Services Secretary Sylvia Burwell yesterday announced a declaration under the Public…

Anti-viralsBavarian NordicBiotechnologyGlaxoSmithKlineJanssenJohnson & JohnsonLegalNewLink GeneticsResearchTropical diseasesUSAVaccines

Spark Thera in potential $280 million hemophilia B deal with Pfizer

Spark Thera in potential $280 million hemophilia B deal with Pfizer

10-12-2014

US gene therapy start up Spark Therapeutics has entered into a global collaboration with pharma giant…

BiotechnologyHematologyLicensingPfizerSpark TherapeuticsSPK-RPE65USA

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

09-12-2014

US pharma major Eli Lilly and partner Incyte Corp today revealed that the Phase III RA-BEACON study of…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteResearchUSA

FDA approves new indication for Amgen's Xgeva

FDA approves new indication for Amgen's Xgeva

08-12-2014

USA-based Amgen says the US Food and Drug Administration has approved a new indication for Xgeva (denosumab),…

AmgenBiotechnologyOncologyRare diseasesRegulationUSAXgeva

US FDA approves new indication for Incyte’s Jakafi

US FDA approves new indication for Incyte’s Jakafi

05-12-2014

The US Food and Drug Administration yesterday approved a new use for Incyte Corp’s Jakafi (ruxolitinib)…

BiotechnologyIncyteJakafiOncologyRegulationUSA

Government action needed to slash prices for hepatitis C treatments, says US advocacy

Government action needed to slash prices for hepatitis C treatments, says US advocacy

04-12-2014

The US federal government should act to dramatically lower the cost of new and prohibitively pricey medications…

Anti-viralsBiotechnologyGilead SciencesPricingSovaldiUSA

US sales of Sanofi/Regeneron’s dupilumab for atopic dermatitis could exceed $1.3 billion by 2022, says analyst

04-12-2014

The first biologic to treat atopic dermatitis, French pharma major Sanofi (Euronext: SAN) and US biotech…

BiotechnologyDermatologicalsdupilumabMarkets & MarketingRegeneron PharmaceuticalsSanofiUSA

US FDA grants earlier approval for Amgen’s Blincyto for rare form of lymphoblastic leukemia

US FDA grants earlier approval for Amgen’s Blincyto for rare form of lymphoblastic leukemia

04-12-2014

Ahead of the anticipated decision date, the US Food and Drug Administration yesterday approved Blincyto…

AmgenBiotechnologyblinatumomabBlincytoOncologyRegulationUSA

Puma shares plummet as it delays NDA filing

Puma shares plummet as it delays NDA filing

03-12-2014

Puma Biotechnology will delay the filing of its New Drug Application (NDA) for the approval of PB272…

BiotechnologyneratinibOncologyPuma BiotechnologyRegulationUSA

A back-to-biology approach to cancer therapies: an interview with Berg's Dr Niven Narain

A back-to-biology approach to cancer therapies: an interview with Berg's Dr Niven Narain

27-11-2014

Massachusetts-based biopharma company Berg is aiming to change the way we treat cancer.

BergBiotechnologyOncologyResearchUSA

Regeneron and Sanofi granted breakthrough designation for dupilumab

Regeneron and Sanofi granted breakthrough designation for dupilumab

25-11-2014

US biotech Regeneron Pharmaceuticals and French pharma major Sanofi have said that the US Food and Drug…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Bristol-Myers Squibb partners with Five Prime on immunotherapy combination trials

Bristol-Myers Squibb partners with Five Prime on immunotherapy combination trials

24-11-2014

US drug major Bristol-Myers Squibb and protein therapeutics specialist Five Prime Therapeutics are to…

BiotechnologyBristol-Myers SquibbFive Prime TherapeuticsOncologyOpdivoResearchUSA

AstraZeneca to invest $200 million in expanding US biologics manufacturing center

22-11-2014

Anglo-Swedish pharma major AstraZeneca on Friday unveiled plants to expand its biologics manufacturing…

AstraZenecaBiotechnologyFinancialMedImmuneProductionUSA

Clovis Oncology's rucaparib achieves positive Phase II results

Clovis Oncology's rucaparib achieves positive Phase II results

20-11-2014

Personalized cancer therapy specialist Clovis Oncology has achieved positive results in a Phase II trial…

BiotechnologyClovis OncologyOncologyResearchrucaparibUSA

Sanofi and Regeneron’s dupilumab gets Breakthrough designation from FDA

20-11-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to French pharma major…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Dicerna licenses rights to Tekmira technology

Dicerna licenses rights to Tekmira technology

18-11-2014

US RNAi therapeutics specialist Dicerna Pharmaceuticals has entered a licensing agreement for to use…

BiotechnologyDCR-PH1Dicerna PharmaceuticalsLicensingRare diseasesTekmira PharmaceuticalsUSA

Merck enters lucrative cancer alliance with Pfizer

Merck enters lucrative cancer alliance with Pfizer

17-11-2014

Germany’s Merck KGaA said today that it has entered into a global agreement with US pharma giant Pfizer…

BiotechnologyGermanyLicensingMarkets & MarketingMerck KGaAMerck SeronoMSB0010718COncologyPfizerUSAXalkori

1 to 25 of 260 results

Back to top